Table II.
Cytotoxicity of three common chemotherapeutic agents, vincristine, melphalan, etoposide, and rapamycin against 23 pediatric cancer cell lines
| Type | Cell line | vincristine | melphalan | etoposide | rapamycin | ||||
|---|---|---|---|---|---|---|---|---|---|
| R-IC50 (nM) | A-IC50 (nM) | R-IC50 (nM) | A-IC50 (nM) | R-IC50 (nM) | A-IC50 (nM) | R-IC50 (nM) | A-IC50 (nM) | ||
| Rhabdomyo-sarcoma | RD | 1.19 ± 0.12 | 1.28 | 3.42 ± 1.09 | 4.24 | 0.19 ± 0.08 | 0.29 | 3.93 ± 0.80 | >100 |
| Rh41 | 0.54 ± 0.04 | 0.57 | 2.16 ± 0.44 | 2.53 | 0.17 ± 0.03 | 0.20 | 0.61 ± 0.04 | 1.32 | |
| Rh18 | 0.19 ± 0.28 | >10 | 17.74 ± 1.38 | 17.77 | 18.80 ± 2.27 | 18.85 | NA* | >100 | |
| Rh30 | 0.30 ± 0.07 | 0.32 | 2.05 ± 0.29 | 2.30 | 0.19 ± 0.03 | 0.21 | 0.73 ± 0.13 | 3.91 | |
| Brain tumor | BT-12 | 0.75 ± 0.05 | 0.77 | 6.32 ± 1.66 | 5.58 | 0.80 ± 0.17 | 0.97 | 1.37 ± 0.37 | >100 |
| SJ-GBM2 | 1.82 ± 0.20 | 2.03 | 2.94 ± 0.23 | 2.84 | 0.26 ± 0.01 | 0.26 | 1.41 ± 0.28 | >100 | |
| CHLA-266 | 1.38 ± 0.15 | 2.20 | 8.37 ± 2.93 | 13.14 | 0.32 ± 0.11 | 0.32 | 0.74 ± 0.09 | >100 | |
| Ewing family of tumors | CHLA-9 | 0.51 ± 0.06 | 0.50 | 0.14 ± 0.06 | 0.14 | 0.01 ± 0.00 | 0.01 | 0.85 ± 0.19 | >100 |
| CHLA-10 | 0.39 ± 0.05 | 0.40 | 7.27 ± 1.20 | 8.71 | 0.12 ± 0.01 | 0.13 | 0.62 ± 0.08 | 1.00 | |
| CHLA-258 | 1.82 ± 0.39 | 1.82 | 3.12 ± 0.53 | 3.49 | 0.03 ± 0.01 | 0.05 | 0.77 ± 0.20 | >100 | |
| TC-71 | 0.34 ± 0.02 | 0.34 | 3.22 ± 0.25 | 3.22 | 0.15 ± 0.01 | 0.15 | NA | >100 | |
| Neuroblastoma | NB-1643 | 0.43 ± 0.03 | 0.49 | 4.70 ± 1.07 | 3.79 | 0.10 ± 0.02 | 0.09 | 0.53 ± 0.24 | >100 |
| NB-EBc1 | 4.92 ± 0.50 | 4.93 | 1.23 ± 0.08 | 1.20 | 0.11 ± 0.01 | 0.10 | 1.18 ± 0.27 | >100 | |
| CHLA-90 | 0.65 ± 0.07 | 0.80 | 7.57 ± 0.98 | 11.16 | 0.45 ± 0.18 | 0.62 | 0.42 ± 0.04 | 2.25 | |
| CHLA-136 | 6.56 ± 1.91 | 6.58 | 3.87 ± 0.48 | 4.50 | 0.34 ± 0.02 | 0.36 | NA | >100 | |
| Leukemia | NALM-6 | 0.71 ± 0.14 | 0.73 | 1.72 ± 0.46 | 1.84 | 0.04 ± 0.00 | 0.04 | 1.71 ± 0.43 | >100 |
| COG-LL-317 | 0.29 ± 0.39 | 0.29 | 1.41 ± 0.14 | >100 | 0.01 ± 0.00 | 0.01 | 0.36 ± 0.06 | 0.59 | |
| RS4-11 | 0.32 ± 0.05 | 0.41 | 1.31 ± 0.14 | 1.31 | 0.03 ± 0.00 | 0.03 | 3.46 ± 3.63 | >100 | |
| MOLT-4 | 0.26 ± 0.01 | 0.27 | 1.47 ± 0.27 | 1.47 | 0.01 ± 0.00 | 0.01 | 0.70 ± 0.05 | 1.23 | |
| CCRF-CEM | 1.57 ± 0.21 | 1.68 | 2.13 ± 0.10 | 2.13 | 0.03 ± 0.00 | 0.03 | 0.35 ± 0.02 | 0.65 | |
| KASUMI-1 | 0.47 ± 0.04 | 0.49 | 4.08 ± 0.76 | 4.08 | 0.17 ± 0.05 | 0.22 | 1.19 ± 0.30 | >100 | |
| Lymphoma | KARPAS-299 | 0.25 ± 0.02 | 0.27 | 2.25 ± 0.43 | 2.18 | 0.10 ± 0.01 | 0.10 | 0.73 ± 0.24 | 1.42 |
| RAMOS | 0.31 ± 0.01 | 0.32 | 4.76 ± 0.61 | 4.65 | 0.03 ± 0.01 | 0.03 | 0.22 ± 0.02 | 0.27 | |
| Median | 0.51 | 0.54 | 3.12 | 3.49 | 0.12 | 0.13 | 0.74 | N/D | |
| Mean | 1.13 | 1.25 | 4.06 | 8.79 | 0.98 | 1.00 | 1.02 | N/D | |
*
Not analyzed because Ymin > 75%; Relative IC50 (R-IC50): value ± SD of estimation; Absolute IC50 (A-IC50) values are calculated using R-IC50 values as described under methods.